Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer Acquires C$29,000.00 in Stock

Medicenna Therapeutics Corp. (TSE:MDNA) Senior Officer David Hyman bought 20,000 shares of Medicenna Therapeutics stock in a transaction dated Thursday, January 9th. The stock was purchased at an average cost of C$1.45 per share, for a total transaction of C$29,000.00.

Medicenna Therapeutics Stock Performance

TSE MDNA opened at C$1.37 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.51 and a quick ratio of 4.65. Medicenna Therapeutics Corp. has a 1-year low of C$0.40 and a 1-year high of C$2.98. The business has a 50 day simple moving average of C$1.78 and a two-hundred day simple moving average of C$2.00. The stock has a market capitalization of C$104.71 million, a PE ratio of -3.61 and a beta of 1.21.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.